UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease
A legfontosabb adatok
- Ki végzi
- The Hospital for Sick Children
- Hol
- Hollandia és Kanada19 helyszín, 2 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 4100 fő, tervezett
- Kezdés
- 2018. aug. 24.
- Várható befejezés
- 2027. márc. 30.
- A vizsgálat típusa
- Megfigyeléses, 4 csoport
- A regiszteradat frissítve
- 2024. augusztus 19.
Ki vehet részt
- Életkor
- Legfeljebb 18 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 23 feltétel megnézéseKevesebb
Ki vehet részt
- Cohort 1: - Biologic Basis of JIA
- ≤18 years*
- Active objective arthritis suspected to be JIA or diagnosed with JIA within 6 months of enrolment
- Treatment naïve except for NSAIDs, allowed to have received NSAIDS within 6 months of diagnosis; Cohort 2 - Start Biologics
- JIA diagnosis as per ILAR criteria (all subtypes)
- ≤18 years*
- Active arthritis
- For sJIA, active disease not necessarily with arthritis
- Time of start, restart or switch biologic therapy: e.g. failure, insufficient/partial response or intolerance; Cohort 3 - Stop Biologics
- JIA diagnosis as per ILAR criteria (all subtypes)
- ≤18 years*
- Inactive disease
- Discontinuing/tapering biologics for inactive disease; Cohort 4: Extreme Phenotypes
- Unexplained systemic inflammation with arthritis/arthralgia as a part of manifestations
- High suspicion of genetic contribution
- Severely affected patients with difficult to control disease (ie failure of multiple biologics)
Ki nem vehet részt
- Joint injections as previous treatment less than 4 weeks prior to enrollment; Cohort 2:
- Cohort 1 :
- Arthritis explained by another diagnosis
- Arthritis explained by any other cause
- Start on biologics as an indication for uveitis only; Cohort 3:
- Tapering scheme > 12 months to complete biologics stop; Cohort 4:
- Arthritis explained by another diagnosis
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
2 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Childhood arthritis is a chronic disabling disease. New medications called biologic therapies are now available to treat arthritis that target key biologic molecules that cause inflammation. Biologic therapies, while very effective in treating arthritis in children, may have serious side effects including infections and potentially cancers, and are very expensive and doctors don't know, which one to choose for which child. The investigators will develop tests that enable them to learn about the biology of each child's arthritis and be able to predict when and which biologic therapy to start and when to stop.
A vizsgálat 4 csoportja
- Cohort 1 - Biologic Basis of JIA
The objectives for this group are to help researchers look at childhood arthritis and determine which management approach is best for each individual child. To be eligible for this group: Participant must be ≤ 18 years of age at time of study enrollment. Participant is suspected to have JIA. Participant has not received any treatment other than non-steroidal anti-inflammatory drugs, such as acetaminophen.
- Cohort 2 - Start Biologics
The objectives for this group are to help researchers develop a tool to predict response to therapy. To be eligible for this group: Participant ≤ 18 years of age at time of study enrollment. Participant has been diagnosed with JIA and arthritis is active. Participant will be starting, re-starting or switching to a new biologic therapy.
- Cohort 3 - Stop Biologics
The objectives for this group are to help researchers develop a tool to predict who will remain in remission after discontinuing therapy. To be eligible for this group: Participant ≤ 18 years of age at time of study enrollment. Participant has been diagnosed with JIA and arthritis is inactive. Participant will be stopping or tapering biologic therapy.
- Cohort 4: Extreme Phenotypes
The objective for this group is new gene discovery and drug target identification. To be eligible for this group: There is high suspicion of genetic contribution. Participants are severely affected with difficult to control arthritis or systemic disease. There is unexplained systemic inflammation with arthritis/arthralgia as a part of manifestations
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2024. augusztus 19.